Page last updated: 2024-12-06

n-n-propylnorapomorphine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-n-propylnorapomorphine: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID167715
CHEMBL ID225230
CHEBI ID92234
SCHEMBL ID7997518
MeSH IDM0053462
PubMed CID30137
SCHEMBL ID249729
MeSH IDM0053462

Synonyms (75)

Synonym
BRD-K13544237-001-01-0
(-)-n-porphynorapomorphine
gtpl969
(9r)-10-propyl-10-azatetracyclo[7.7.1.0^{2,7}.0^{13,17}]heptadeca-1(17),2,4,6,13,15-hexaene-3,4-diol
win-28928
n-propylnorapomorphine
(r)-6-propyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
PDSP2_000840
PDSP2_000839
BIOMOL-NT_000080
PDSP1_000852
BPBIO1_001404
PDSP1_001509
PDSP1_000853
LOPAC0_000435
PDSP2_001493
propylnorapomorphine
n-propylapomorphine
NCGC00162153-03
r-n-propylnorapomorphine
18426-20-5
(6ar)-6-propyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
n-propylnorapomorphine-(+)
(r)-10,11-dihydroxy-6-propyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinolinium
(+)-6-propyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
n-propylnorapomorphine-(-)
(r) 6-propyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
(-)-6-propyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
10,11-dihydroxy-6-propyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinolinium(r(-)npa)
bdbm50007422
CHEMBL225230 ,
skf-76783
bdbm50012994
cid_11957529
6-propyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol; hydrochloride
CCG-204527
noraporphine-10,11-diol, 6-propyl-
6-propylnoraporphine-10,11-diol
unii-nh381p1br8
nh381p1br8 ,
(-)-npa
(-)-n-propylnorapomorphine
(-)-6-propylnorapomorphine
4h-dibenzo[de,g]quinoline-10,11-diol,5,6,6a,7-tetrahydro-6-propyl-, (6ar)-
SCHEMBL7997518
CHEBI:92234
4h-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-propyl-, (6ar)-
r(-)-10,11-dihydroxy-n-n-propylnoraporphine
DTXSID50939811
Q27088028
SDCCGSBI-0050420.P002
10-propyl-10-azatetracyclo[7.7.1.0^{2,7}.0^{13,17}]heptadeca-1(17),2,4,6,13,15-hexaene-3,4-diol
gtpl934
PDSP2_000775
NCGC00162153-02
n-n-propylnorapomorphine
4h-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-propyl-
PDSP1_000787
NCGC00162153-01
L000005
6-propyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
6-propyl- 5,6,6a,7-tetrahydro-4h-dibenzo(de,g)quinoline-10,11-diol
(+-)-n-propylnorapomorphine
unii-az9l8zyz3a
4h-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-propyl-, (+-)-
10,11-dihydroxy-6-propylnoraporphine
57559-68-9
az9l8zyz3a ,
(+-)-n-n-propylnorapomorphine
SCHEMBL249729
Q27088032
(+/-)-n-n-propylnorapomorphine
propylnorapomorphine, (+/-)-
(+/-)-n-propylnorapomorphine
DTXSID001311565

Research Excerpts

Dosage Studied

Irreversible inactivation of striatal D2 dopamine (DA) autoreceptors with N-ethoxycarbonyl-2-ethoxide-1,2-dihydroquinoline or pertussis toxin (PT) shifted the dose-response curve for N-n-propylnorapomorphine (NPA) The inhibition of A9 and A10 dopamine cell firing by intravenous administration of the potent dopamine agonist, NPA, led to a decrease in the maximum response.

ExcerptRelevanceReference
" The dose-response curve of the mimetic was found to exhibit a down-turn phase, similar to that of PLG."( Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold.
Boström, D; Del Tredici, AL; Kihlberg, J; Luthman, K; Mohell, N; Saitton, S; Vollinga, RC, 2004
)
0.32
"Irreversible inactivation of striatal D2 dopamine (DA) autoreceptors with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) or inactivation of striatal guanine nucleotide binding proteins (G proteins) with pertussis toxin (PT) shifted the dose-response curve for N-n-propylnorapomorphine (NPA)-mediated inhibition of gamma-butyrolactone (GBL)-induced elevation of L-3,4-dihydroxyphenylalanine (L-DOPA) to the right, with a decrease in the maximum response."( The effects of pertussis toxin on dopamine D2 and serotonin 5-HT1A autoreceptor-mediated inhibition of neurotransmitter synthesis: relationship to receptor reserve.
Bohmaker, K; Bordi, F; Meller, E, 1992
)
0.46
" Since the behavioural effects of B-HT 920 vary according to the dosage employed, discussion centres on what receptors might conceivably underly these effects and on their preclinical relevance."( Effects of B-HT 920 in the tail-suspension test.
Cassinadri, M; Ferrari, F; Tampieri, A; Tartoni, PL, 1991
)
0.28
" In the first series of experiments, dose-response curves were constructed for the inhibition of A9 and A10 dopamine cell firing by intravenous administration of the potent dopamine agonist, R-(-)-N-n-propylnorapomorphine (NPA)."( Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis.
Cox, RF; Waszczak, BL, 1990
)
0.47
" However, antagonist properties were also evident inasmuch as immediate pretreatment with a low dose of (S)-(+)-NPA caused a significant rightward shift of the (R)-(-)-NPA dose-response curve."( Differences in dopamine receptor reserve for N-n-propylnorapomorphine enantiomers: single unit recording studies after partial inactivation of receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
Cox, RF; Waszczak, BL, 1989
)
0.54
" Pretreatment with sulpiride (200 mg/kg) produced a parallel, 40-fold shift to the right of the dose-response curve for NPA."( Hypothermia in mice: D2 dopamine receptor mediation and absence of spare receptors.
Hizami, R; Kreuter, L; Meller, E, 1989
)
0.28
" However, when N-propylnorapomorphine was administered on a subchronic dosage schedule, no antipsychotic effect occurred."( Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine.
Alphs, LD; Foster, NL; Gotts, MD; Tamminga, CA; Thaker, GK, 1986
)
0.27
" After irreversible dopamine (DA) receptor inactivation with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), neither the ED50 nor the slope of the dose-response curve for NPA was altered, whereas the maximal response was reduced to 56% of control."( Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity.
Enz, A; Goldstein, M; Meller, E, 1988
)
0.27
"The effects of long-term dosing with tiapride for 21 days on barin dopamine receptors and dopamine turnover were compared with those of sulpiride and haloperidol."( Effect of long-term dosing with tiapride on brain dopamine receptors and metabolism in rats. Comparative study with sulpiride and haloperidol.
Kohjimoto, Y; Kuwaki, T; Nomura, Y; Ono, T; Satoh, H; Shibayama, F; Shirakawa, K, 1987
)
0.27
" Seven DA agonists produced U-shaped dose-response curves indicative of activity at both the autoreceptor and postsynaptic DA receptor."( Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation.
Bendesky, RJ; Martin, GE, 1984
)
0.27
" Lactotroph-enriched cell cultures displayed similar functional characteristics as untreated cells when assessed by determining dose-response curves for inhibition of PRL secretion by the DA agonist N-propylnorapomorphine."( A novel method for rapid enrichment of lactotrophs from dispersed anterior pituitary cells of the rat.
Bohmaker, K; Diamond, J; Goldstein, M; Lew, JY; Meller, E; Okrongly, D; Puza, T; Schütte, M, 1993
)
0.29
" Moreover, dose-response curves to R(-)-NPA were shifted 10-fold to the right and the maximum inhibitory response was depressed."( Inhibition of substantia nigra dopamine cell firing by R(-)-N-n-propylnorapomorphine: electrophysiological and autoradiographic studies after regional inactivation of dopamine receptors by microinjection of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
Cox, RF; Waszczak, BL, 1993
)
0.53
" l-Nafadotride displaces in vivo N-[3H]propylnorapomorphine accumulation at lower dosage and for longer periods in limbic structures, containing both dopamine D2 and D3 receptors than in the stratum, containing dopamine D2 receptor only."( Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Costentin, J; Garrido, F; Griffon, N; Launay, C; Mann, A; Sautel, F; Schoenfelder, A; Schwartz, JC; Simon, P; Sokoloff, P, 1995
)
0.29
" NPA dose-response curves for reversal of GBL-induced dopa accumulation and Ser40 phosphorylation were identical; however, only the highest dose of NPA reversed the small and variable increase in Ser19 phosphorylation."( Increased site-specific phosphorylation of tyrosine hydroxylase accompanies stimulation of enzymatic activity induced by cessation of dopamine neuronal activity.
Carr, KD; Garcia-Espana, A; Goldstein, M; Haycock, JW; Lee, KY; Lew, JY; Meller, E, 1999
)
0.3
" The dose-response curve of the mimetic was found to exhibit a down-turn phase, similar to that of PLG."( Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold.
Boström, D; Del Tredici, AL; Kihlberg, J; Luthman, K; Mohell, N; Saitton, S; Vollinga, RC, 2004
)
0.32
" drug injection, combining heroin with cocaine shifted the heroin dose-response function leftward, and isobolographic analysis indicated that the combined effects were dose-additive."( Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys.
Platt, DM; Rowlett, JK; Spealman, RD; Yao, WD, 2007
)
0.34
" All derivatives produced a bell-shaped dose-response curve and none of the compounds were active at the D2 receptor alone, which indicates that the mechanism behind the activity of both the pyridine based mimetics and PLG is the same."( Synthesis and evaluation of novel pyridine based PLG tripeptidomimetics.
Del Tredici, AL; Kihlberg, J; Luthman, K; Saitton, S; Saxin, M; Stenström, T, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aporphine alkaloidAny benzylisoquinoline alkaloid that has a structure based on 4H-dibenzo[de,g]quinoline or its 3-methyl derivative.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dopamine D1 receptorHomo sapiens (human)Potency0.04610.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency19.82450.100020.879379.4328AID488773; AID588453; AID588456
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
GLS proteinHomo sapiens (human)Potency1.41250.35487.935539.8107AID624146
hypothetical protein, conservedTrypanosoma bruceiPotency6.74560.223911.245135.4813AID624147
regulator of G-protein signaling 4Homo sapiens (human)Potency1.49890.531815.435837.6858AID504845
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
arylsulfatase AHomo sapiens (human)Potency4.77551.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.68340.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency0.27820.02245.944922.3872AID488981; AID488982; AID488983
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency7.94330.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency70.79460.006026.168889.1251AID488953
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency26.12160.00378.618923.2809AID2668
DNA polymerase kappa isoform 1Homo sapiens (human)Potency37.68580.031622.3146100.0000AID588579
M-phase phosphoprotein 8Homo sapiens (human)Potency23.77810.177824.735279.4328AID488949
Ataxin-2Homo sapiens (human)Potency25.11890.011912.222168.7989AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency11.99550.060110.745337.9330AID485368
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency3.66260.000811.382244.6684AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency22.98330.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.58490.035520.977089.1251AID504332
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine 3-monooxygenaseHomo sapiens (human)IC50 (µMol)0.30000.30000.51000.7200AID313108
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)0.00000.00000.74728.0000AID62635
D(2) dopamine receptorHomo sapiens (human)Ki0.05000.00000.651810.0000AID63227
DRattus norvegicus (Norway rat)IC50 (µMol)0.31950.00030.50267.7625AID45982; AID45983; AID61026
DRattus norvegicus (Norway rat)Ki1.49330.00010.610010.0000AID313111; AID317240; AID61497
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.23940.00030.39075.4000AID45982; AID45983
D(2) dopamine receptorBos taurus (cattle)Ki0.00150.00000.58366.1000AID62464
D(1A) dopamine receptorHomo sapiens (human)Ki0.87770.00010.836310.0000AID569899; AID569900; AID63040
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.23940.00030.35635.4000AID45982; AID45983
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.23940.00030.38715.4000AID45982; AID45983
D(3) dopamine receptorHomo sapiens (human)Ki0.00040.00000.602010.0000AID569901
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.19250.00010.54948.4000AID45982; AID45983; AID61403
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.01320.00000.437510.0000AID313112; AID317241; AID569896; AID569897; AID65113
DBos taurus (cattle)Ki0.00150.00012.367610.0000AID62464
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)EC50 (µMol)0.00550.00000.18743.9000AID1547938; AID1547942; AID282086
D(2) dopamine receptorHomo sapiens (human)Kd0.02000.00000.64599.5000AID64315
D(1A) dopamine receptorHomo sapiens (human)EC50 (µMol)0.93710.00020.47959.5000AID1547936; AID1547940
D(1A) dopamine receptorHomo sapiens (human)Kd1.81600.02801.27634.6000AID61865
D(2) dopamine receptorRattus norvegicus (Norway rat)Kd0.18960.00030.81836.7000AID64790; AID64917; AID64919; AID64925
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)KL0.62500.02100.44030.7340AID61996
D(2) dopamine receptorRattus norvegicus (Norway rat)KL0.02300.02300.49531.0000AID64788
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (193)

Processvia Protein(s)Taxonomy
response to hypoxiaTyrosine 3-monooxygenaseHomo sapiens (human)
synaptic transmission, dopaminergicTyrosine 3-monooxygenaseHomo sapiens (human)
response to amphetamineTyrosine 3-monooxygenaseHomo sapiens (human)
heart morphogenesisTyrosine 3-monooxygenaseHomo sapiens (human)
dopamine biosynthetic process from tyrosineTyrosine 3-monooxygenaseHomo sapiens (human)
fatty acid metabolic processTyrosine 3-monooxygenaseHomo sapiens (human)
sphingolipid metabolic processTyrosine 3-monooxygenaseHomo sapiens (human)
heart developmentTyrosine 3-monooxygenaseHomo sapiens (human)
visual perceptionTyrosine 3-monooxygenaseHomo sapiens (human)
learningTyrosine 3-monooxygenaseHomo sapiens (human)
memoryTyrosine 3-monooxygenaseHomo sapiens (human)
mating behaviorTyrosine 3-monooxygenaseHomo sapiens (human)
locomotory behaviorTyrosine 3-monooxygenaseHomo sapiens (human)
regulation of heart contractionTyrosine 3-monooxygenaseHomo sapiens (human)
response to light stimulusTyrosine 3-monooxygenaseHomo sapiens (human)
response to herbicideTyrosine 3-monooxygenaseHomo sapiens (human)
response to salt stressTyrosine 3-monooxygenaseHomo sapiens (human)
anatomical structure morphogenesisTyrosine 3-monooxygenaseHomo sapiens (human)
animal organ morphogenesisTyrosine 3-monooxygenaseHomo sapiens (human)
response to zinc ionTyrosine 3-monooxygenaseHomo sapiens (human)
response to activityTyrosine 3-monooxygenaseHomo sapiens (human)
aminergic neurotransmitter loading into synaptic vesicleTyrosine 3-monooxygenaseHomo sapiens (human)
glycoside metabolic processTyrosine 3-monooxygenaseHomo sapiens (human)
phthalate metabolic processTyrosine 3-monooxygenaseHomo sapiens (human)
cerebral cortex developmentTyrosine 3-monooxygenaseHomo sapiens (human)
response to nutrient levelsTyrosine 3-monooxygenaseHomo sapiens (human)
response to estradiolTyrosine 3-monooxygenaseHomo sapiens (human)
response to lipopolysaccharideTyrosine 3-monooxygenaseHomo sapiens (human)
isoquinoline alkaloid metabolic processTyrosine 3-monooxygenaseHomo sapiens (human)
social behaviorTyrosine 3-monooxygenaseHomo sapiens (human)
response to isolation stressTyrosine 3-monooxygenaseHomo sapiens (human)
response to immobilization stressTyrosine 3-monooxygenaseHomo sapiens (human)
terpene metabolic processTyrosine 3-monooxygenaseHomo sapiens (human)
dopamine biosynthetic processTyrosine 3-monooxygenaseHomo sapiens (human)
epinephrine biosynthetic processTyrosine 3-monooxygenaseHomo sapiens (human)
norepinephrine biosynthetic processTyrosine 3-monooxygenaseHomo sapiens (human)
eye photoreceptor cell developmentTyrosine 3-monooxygenaseHomo sapiens (human)
circadian sleep/wake cycleTyrosine 3-monooxygenaseHomo sapiens (human)
eating behaviorTyrosine 3-monooxygenaseHomo sapiens (human)
response to peptide hormoneTyrosine 3-monooxygenaseHomo sapiens (human)
pigmentationTyrosine 3-monooxygenaseHomo sapiens (human)
response to ethanolTyrosine 3-monooxygenaseHomo sapiens (human)
response to etherTyrosine 3-monooxygenaseHomo sapiens (human)
response to pyrethroidTyrosine 3-monooxygenaseHomo sapiens (human)
embryonic camera-type eye morphogenesisTyrosine 3-monooxygenaseHomo sapiens (human)
response to corticosteroneTyrosine 3-monooxygenaseHomo sapiens (human)
response to electrical stimulusTyrosine 3-monooxygenaseHomo sapiens (human)
phytoalexin metabolic processTyrosine 3-monooxygenaseHomo sapiens (human)
cellular response to manganese ionTyrosine 3-monooxygenaseHomo sapiens (human)
cellular response to alkaloidTyrosine 3-monooxygenaseHomo sapiens (human)
cellular response to nicotineTyrosine 3-monooxygenaseHomo sapiens (human)
cellular response to glucose stimulusTyrosine 3-monooxygenaseHomo sapiens (human)
cellular response to growth factor stimulusTyrosine 3-monooxygenaseHomo sapiens (human)
cellular response to xenobiotic stimulusTyrosine 3-monooxygenaseHomo sapiens (human)
hyaloid vascular plexus regressionTyrosine 3-monooxygenaseHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicDBos taurus (cattle)
vasodilationDBos taurus (cattle)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
tyrosine 3-monooxygenase activityTyrosine 3-monooxygenaseHomo sapiens (human)
protein bindingTyrosine 3-monooxygenaseHomo sapiens (human)
ferrous iron bindingTyrosine 3-monooxygenaseHomo sapiens (human)
ferric iron bindingTyrosine 3-monooxygenaseHomo sapiens (human)
amino acid bindingTyrosine 3-monooxygenaseHomo sapiens (human)
oxygen bindingTyrosine 3-monooxygenaseHomo sapiens (human)
enzyme bindingTyrosine 3-monooxygenaseHomo sapiens (human)
protein domain specific bindingTyrosine 3-monooxygenaseHomo sapiens (human)
tetrahydrobiopterin bindingTyrosine 3-monooxygenaseHomo sapiens (human)
dopamine bindingTyrosine 3-monooxygenaseHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
nucleusTyrosine 3-monooxygenaseHomo sapiens (human)
cytoplasmTyrosine 3-monooxygenaseHomo sapiens (human)
mitochondrionTyrosine 3-monooxygenaseHomo sapiens (human)
smooth endoplasmic reticulumTyrosine 3-monooxygenaseHomo sapiens (human)
cytosolTyrosine 3-monooxygenaseHomo sapiens (human)
synaptic vesicleTyrosine 3-monooxygenaseHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine 3-monooxygenaseHomo sapiens (human)
dendriteTyrosine 3-monooxygenaseHomo sapiens (human)
cytoplasmic vesicleTyrosine 3-monooxygenaseHomo sapiens (human)
melanosome membraneTyrosine 3-monooxygenaseHomo sapiens (human)
neuron projectionTyrosine 3-monooxygenaseHomo sapiens (human)
terminal boutonTyrosine 3-monooxygenaseHomo sapiens (human)
perikaryonTyrosine 3-monooxygenaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosine 3-monooxygenaseHomo sapiens (human)
perikaryonTyrosine 3-monooxygenaseHomo sapiens (human)
cytoplasmTyrosine 3-monooxygenaseHomo sapiens (human)
axonTyrosine 3-monooxygenaseHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneDBos taurus (cattle)
dendritic spineDBos taurus (cattle)
ciliary membraneDBos taurus (cattle)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (109)

Assay IDTitleYearJournalArticle
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID45982Inhibition of [3H]apomorphine binding to calf caudate membrane preparation (p4)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
AID1131428Antagonism of dopamine-induced hyperactivity in sc dosed Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway after 2.5 hrs treated bilateral injection of 50 ug of dopamine into the nucleus accumbens1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID64925In vitro affinity at wild type Dopamine receptor D2 on C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID61497Binding affinity at rat striatal Dopamine receptor D1 using [3H]- SCH-23390 radioligand1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
AID64788Low-affinity agonist dissociation constant against striatal Dopamine receptor D21996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID1150399Central dopaminergic activity in 6-OH-DA-lesioned ip dosed specific pathogen-free Sprague-Dawley rat assessed as induction of rotational behavior1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine.
AID1547942Agonist activity at D2 long receptor (unknown origin) transfected in human HEK293T cells assessed as increase in cAMP accumulation incubated for 2 hrs by cAMP Glo-sensor assay2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID1150398Central dopaminergic activity in 6-OH-DA-lesioned specific pathogen-free Sprague-Dawley rat assessed as induction of rotational behavior measured as total time at 0.005 mg/kg, ip1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine.
AID282086Activity at human dopamine D2 receptor in NIH/3T3 cells assessed as beta-galactosidase activity after 5 days by R-SAT assay2004Journal of medicinal chemistry, Dec-16, Volume: 47, Issue:26
Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold.
AID1547936Agonist activity at C-terminal RLuc8-fused D1R (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine 2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID34459Dopamine sensitive adenylate cyclase activity (stimulation) in homogenates of rat brain striatal tissue was assessed at 50 uM of compound; ++ = 41-60% incresae of cAMP above basal activity1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
AID61867log(1/Kd) value against recombinant Dopamine receptor D1A expressed in COS7 cell1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID1131405Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as sniffing and repetitive head and limb movements at 0.0063 to 0.05 mg/kg, sc1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID62464Agonistic activity against calf striatal Dopamine receptor using [3H]- ADTN radioligand1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
AID65113Binding affinity at rat striatal Dopamine receptor D2 using [3H]- piperone radioligand1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
AID569896Displacement of [3H]SCH23390 from dopamine D2 receptor low binding site in Sprague-Dawley rat striatum by scintillation counting2011ACS medicinal chemistry letters, Mar-10, Volume: 2, Issue:3
Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 Receptors
AID1150390Central dopaminergic activity in 6-OH-DA-lesioned specific pathogen-free Sprague-Dawley rat assessed as induction of rotational behavior measured as total time at 0.025 mg/kg, ip1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine.
AID61403Binding affinity against Dopamine receptor D2 from rat brain corpus striatum membrane1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and dopamine receptor affinity of (R)-(-)-2-fluoro-N-n-propylnorapomorphine: a highly potent and selective dopamine D2 agonist.
AID61026Binding affinity against Dopamine receptor D1 from rat brain corpus striatum membrane1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and dopamine receptor affinity of (R)-(-)-2-fluoro-N-n-propylnorapomorphine: a highly potent and selective dopamine D2 agonist.
AID34170Compound was evaluated for the elicited effect on adenylate cyclase activity in homogenates of carp retina at 100 uM1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Aporphines. 34. (-)-2,10,11-Trihydroxy-N-n-propylnoraporphine, a novel dopaminergic aporphine alkaloid with anticonvulsant activity.
AID1547945Bias factor, transduction co-efficient for agonist activity at D2 long receptor (unknown origin) transfected in human HEK293T cells assessed as increase in cAMP accumulation incubated for 2 hrs by cAMP Glo-sensor assay based Kean-kin method2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID1131414Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as sniffing behavior at 25 mg/kg, bilateral intrastriatal1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID1131400Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as continuous biting at 0.1 mg/kg, sc1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID313108Inhibition of tyrosine hydroxylase2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID62635Agonist required to inhibit Dopamine receptor D2 photoinactivation by 50% with Iodazidoclebopride using [3H]-Spiperone1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Novel photoaffinity label for the dopamine D2 receptor: synthesis of 4-azido-5-iodo-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl] benzamide (iodoazidoclebopride, IAC) and the corresponding 125I-labeled analogue (125IAC).
AID313107Inhibition of rat midbrain dopaminergic neuron firing2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID34168Compound was evaluated for the elicited effect on adenylate cyclase activity in homogenates of carp retina at 10 uM1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Aporphines. 34. (-)-2,10,11-Trihydroxy-N-n-propylnoraporphine, a novel dopaminergic aporphine alkaloid with anticonvulsant activity.
AID1131427Behavioral responses in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as hyperactivity response at 3.125 to 25 mg/kg direct injection into nucleus accumbens1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID1150391Central dopaminergic activity in 6-OH-DA-lesioned specific pathogen-free Sprague-Dawley rat assessed as induction of rotational behavior measured as total time at 0.05 mg/kg, ip1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine.
AID64315Equilibrium dissociation constant against recombinant Dopamine receptor D2A expressed in COS7 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID313112Displacement of [3H]raclopride from rat dopamine D2 receptor2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID1547944Bias factor, transduction co-efficient for agonist activity at D1R (unknown origin) transfected in human HEK293T cells assessed as increase in cAMP accumulation incubated for 2 hrs by cAMP Glo-sensor assay based Kena-kin method2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID1150397Central dopaminergic activity in 6-OH-DA-lesioned specific pathogen-free Sprague-Dawley rat assessed as induction of rotational behavior measured as total time at 0.1 mg/kg, ip1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine.
AID1547941Agonist activity at D1R (unknown origin) transfected in human HEK293T cells assessed as increase in cAMP accumulation incubated for 2 hrs by cAMP Glo-sensor assay relative to control2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID569897Displacement of [3H]domperidone from dopamine D2 receptor high binding site in Sprague-Dawley rat striatum by scintillation counting2011ACS medicinal chemistry letters, Mar-10, Volume: 2, Issue:3
Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 Receptors
AID1131426Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as sniffing behavior at 25 mg/kg direct injection into nucleus accumbens1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID1150385Antinociceptive activity in naloxone hydrochloride-pretreated albino CD-1 mouse at 0.1 to 10 mg/kg, ip after 10 mins by tail-flick method1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine.
AID226917Ratio of binding affinity of D2 to binding affinity of D11990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
AID1131411Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as maximal biting behavior at 25 mg/kg direct injection into nucleus accumbens1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID61865Equilibrium dissociation constant against recombinant Dopamine receptor D1A expressed in COS7 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID45983Inhibition of [3H]spiroperidol binding to calf caudate membrane preparation (p4)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
AID521208Antiproliferative activity against mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1150401Antinociceptive activity in albino CD-1 mouse at 0.1 to 10 mg/kg, ip after 10 mins by tail-flick method1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine.
AID64790In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID1131408Behavioral responses in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as bilateral response at 6.25 to 25 mg/kg direct injection into caudate-putamen1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID64919In vitro affinity at mutant D2 receptor (S197A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID61506Compound was evaluated for its ability to inhibit dopamine receptor D1 in rat striatum using [3H]SCH-233901991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue.
AID1131416Behavioral responses in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as hyperactivity response at 25 mg/kg, bilateral intrastriatal1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID226743Potency ratio calculated from the ratio of D2 to that of D1 receptors1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue.
AID521209Antiproliferative activity against mouse astrocyte cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1547943Agonist activity at D2 long receptor (unknown origin) transfected in human HEK293T cells assessed as increase in cAMP accumulation incubated for 2 hrs by cAMP Glo-sensor assay relative to control2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID1131424Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as biting behavior at 3.125 to 25 mg/kg direct injection into nucleus accumbens1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID61996Low-affinity agonist dissociation constant against striatal Dopamine receptor D1A1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
AID521215Antiproliferative activity against mouse neural precursor cells by colony formation assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1547938Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of co2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID1131415Stereotyped behavior in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as biting behavior at 25 mg/kg, bilateral intrastriatal1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID1131409Behavioral responses in Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as hyperactivity response at 6.25 to 25 mg/kg direct injection into caudate-putamen1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID1131398Circling behavior in sc dosed Sprague-Dawley rat with unilateral 6-OHDA lesion of nigrostriatal pathway assessed as number of revolutions performed per min1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
AID64917In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID1547940Agonist activity at D1R (unknown origin) transfected in human HEK293T cells assessed as increase in cAMP accumulation incubated for 2 hrs by cAMP Glo-sensor assay2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID34460Dopamine sensitive adenylate cyclase activity (stimulation) in homogenates of rat brain striatal tissue was assessed at 50 uM of compound; +++ = 61-80% incresae of cAMP above basal activity1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
AID317240Displacement of [3H]SCH-23390 from dopamine D1 receptor in rat striatum2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity.
AID317242Selectivity ratio of rat dopamine D2 receptor to rat dopamine D1 receptor2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity.
AID61813Compound was evaluated for its ability to inhibit Striatal Dopamine Receptor in rat brain through radioreceptor assay carried out with agonist ligand.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue.
AID63227Affinity towards Dopamine receptor D21998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID521210Ratio of EC50 for mouse astrocytes to EC50 for mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID569900Binding affinity to dopamine D1 receptor high binding site by radioligand displacement assay2011ACS medicinal chemistry letters, Mar-10, Volume: 2, Issue:3
Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 Receptors
AID112341Evaluated for audiogenic seizures in DBA/ 2 mice, in the protection against paroxysimal EEG at an interval of 30 minutes1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Aporphines. 34. (-)-2,10,11-Trihydroxy-N-n-propylnoraporphine, a novel dopaminergic aporphine alkaloid with anticonvulsant activity.
AID226901Potency ratio as ratio of IC50 of D2 receptor to that of D1 receptor1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and dopamine receptor affinity of (R)-(-)-2-fluoro-N-n-propylnorapomorphine: a highly potent and selective dopamine D2 agonist.
AID1150389Central dopaminergic activity in 6-OH-DA-lesioned specific pathogen-free Sprague-Dawley rat assessed as induction of rotational behavior measured as total time at 0.01 mg/kg, ip1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Aporphines. 14 Dopaminergic and antinociceptive activity of aporphine derivatives. Synthesis of 10-hydroxyaporphines and 10-hydroxy-N-n-propylnoraporphine.
AID521214Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID313111Displacement of [3H]SCH-23390 from rat dopamine D1 receptor2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Advances in development of dopaminergic aporphinoids.
AID65277Compound was evaluated for its ability to inhibit dopamine receptor D2 in rat striatum using [3H]-spiperone1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
R and S enantiomers of 11-hydroxy- and 10,11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue.
AID155431Duration of protection for abolition of myoclonic responses to photic stimulation in the baboon (Papio papio) at 0.2 mg/kg1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Aporphines. 34. (-)-2,10,11-Trihydroxy-N-n-propylnoraporphine, a novel dopaminergic aporphine alkaloid with anticonvulsant activity.
AID569901Displacement of [3H]domperidone from human dopamine D3 receptor expressed in human HEK293 cells by scintillation counting2011ACS medicinal chemistry letters, Mar-10, Volume: 2, Issue:3
Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 Receptors
AID317241Displacement of [3H]neomonapride from dopamine D2 receptor in rat striatum2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity.
AID1547937Agonist activity at C-terminal RLuc8-fused D1R (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine 2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID63040Affinity towards Dopamine receptor D11998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID1547939Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of co2020ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.
AID64284Evaluated for the affinity against Dopamine receptor D2 in rat striatal membranes1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Preparation of 7-oxaaporphine derivatives and evaluation of their dopaminergic activity.
AID569899Binding affinity to dopamine D1 receptor low binding site by radioligand displacement assay2011ACS medicinal chemistry letters, Mar-10, Volume: 2, Issue:3
Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 Receptors
AID1345833Human D3 receptor (Dopamine receptors)1995Neuroreport, Jan-26, Volume: 6, Issue:2
A functional test identifies dopamine agonists selective for D3 versus D2 receptors.
AID1345788Human D2 receptor (Dopamine receptors)1995Neuroreport, Jan-26, Volume: 6, Issue:2
A functional test identifies dopamine agonists selective for D3 versus D2 receptors.
AID1345833Human D3 receptor (Dopamine receptors)1994The Journal of pharmacology and experimental therapeutics, Jan, Volume: 268, Issue:1
Expression and pharmacological characterization of the human D3 dopamine receptor.
AID1345788Human D2 receptor (Dopamine receptors)1994The Journal of pharmacology and experimental therapeutics, Jan, Volume: 268, Issue:1
Expression and pharmacological characterization of the human D3 dopamine receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1345718Human D1 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1345879Human D5 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (299)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990154 (51.51)18.7374
1990's81 (27.09)18.2507
2000's37 (12.37)29.6817
2010's21 (7.02)24.3611
2020's6 (2.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.50 (24.57)
Research Supply Index5.63 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials4 (1.46%)5.53%
Reviews1 (3.23%)6.00%
Reviews3 (1.09%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
Other267 (97.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]